LPRS3
MCID: LPR021
MIFTS: 71

Leprosy 3 (LPRS3)

Categories: Eye diseases, Genetic diseases, Immune diseases, Infectious diseases, Neuronal diseases, Rare diseases, Reproductive diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Leprosy 3

MalaCards integrated aliases for Leprosy 3:

Name: Leprosy 3 57
Leprosy 57 11 19 42 58 75 43 14 16 71 33
Leprosy, Susceptibility to, 3 57 28 5
Hansen's Disease 19 42 2
Infection Due to Mycobacterium Leprae 42 33
Leprosy, Susceptibility to 57 12
Hansen Disease 42 33
Maculoanaesthetic Leprosy 33
Anaesthesia Leprosy 33
Anaesthetic Leprosy 33
Leprosy Unspecified 33
Leprosy, Type 3 38
Macular Leprosy 33
Lprs3 57

Characteristics:


Inheritance:

Leprosy 3: Autosomal dominant 57
Leprosy: Multigenic/multifactorial 58

Prevelance:

Leprosy: 1-9/100000 (Worldwide) 58

Age Of Onset:

Leprosy: All ages 58

OMIM®:

57 (Updated 08-Dec-2022)
Miscellaneous:
see for a discussion on leprosy susceptibility


Classifications:

Orphanet: 58  
Rare neurological diseases
Rare infertility disorders
Rare infectious diseases


Summaries for Leprosy 3

MedlinePlus Genetics: 42 Leprosy, also called Hansen disease, is a disorder known since ancient times. It is caused by bacteria called Mycobacterium leprae and is contagious, which means that it can be passed from person to person. It is usually contracted by breathing airborne droplets from affected individuals' coughs and sneezes, or by coming into contact with their nasal fluids. However, it is not highly transmissible, and approximately 95 percent of individuals who are exposed to Mycobacterium leprae never develop leprosy. The infection can be contracted at any age, and signs and symptoms can take anywhere from several months to 20 years to appear.Leprosy affects the skin and the peripheral nerves, which connect the brain and spinal cord to muscles and to sensory cells that detect sensations such as touch, pain, and heat. Most affected individuals have areas of skin damage (cutaneous lesions) and problems with nerve function (peripheral neuropathy); however, the severity and extent of the problems vary widely. Leprosy occurs on a spectrum, in which the most severe form is called multibacillary or lepromatous, and the least severe form is called paucibacillary or tuberculoid. Patterns of signs and symptoms intermediate between these forms are sometimes called borderline forms.Multibacillary leprosy usually involves a large number of cutaneous lesions, including both surface damage and lumps under the skin (nodules). The moist tissues that line body openings such as the eyelids and the inside of the nose and mouth (mucous membranes) can also be affected, which can lead to vision loss, destruction of nasal tissue, or impaired speech. Some affected individuals have damage to internal organs and tissues. The nerve damage that occurs in multibacillary leprosy often results in a lack of sensation in the hands and feet. Repeated injuries that go unnoticed and untreated because of this lack of sensation can lead to reabsorption of affected fingers or toes by the body, resulting in the shortening or loss of these digits.Paucibacillary leprosy typically involves a small number of surface lesions on the skin. There is generally loss of sensation in these areas, but the other signs and symptoms that occur in multibacillary leprosy are less likely to develop in this form of the disorder.In any form of leprosy, episodes called reactions can occur, and can lead to further nerve damage. These episodes can include reversal reactions, which involve pain and swelling of the skin lesions and the nerves in the hands and feet. People with the more severe forms of leprosy can develop a type of reaction called erythema nodosum leprosum (ENL). These episodes involve fever and painful skin nodules. In addition, painful, swollen nerves can occur. ENL can also lead to inflammation of the joints, eyes, and the testicles in men.Leprosy has long been stigmatized because of its infectious nature and the disfigurement it can cause. This stigma can cause social and emotional problems for affected individuals. However, modern treatments can prevent leprosy from getting worse and spreading to other people. While the infection is curable, nerve and tissue damage that occurred before treatment is generally permanent.

MalaCards based summary: Leprosy 3, also known as leprosy, is related to borderline leprosy and indeterminate leprosy, and has symptoms including skin lesions, sensory loss and motor loss. An important gene associated with Leprosy 3 is TLR2 (Toll Like Receptor 2), and among its related pathways/superpathways are Innate Immune System and Akt Signaling. The drugs Levoleucovorin and Folic acid have been mentioned in the context of this disorder. Affiliated tissues include superficial peripheral nerves, skin and mucous membranes of the upper respiratory tract, and related phenotypes are skeletal muscle atrophy and hyperkeratosis

CDC: 2 Hansen's disease (also known as leprosy) is an infection caused by slow-growing bacteria called Mycobacterium leprae. It can affect the nerves, skin, eyes, and lining of the nose (nasal mucosa). With early diagnosis and treatment, the disease can be cured. People with Hansen's disease can continue to work and lead an active life during and after treatment. Leprosy was once feared as a highly contagious and devastating disease, but now we know it doesn't spread easily and treatment is very effective. However, if left untreated, the nerve damage can result in crippling of hands and feet, paralysis, and blindness.

GARD: 19 Hansen's disease (also known as leprosy) is a rare bacterial infection that affects the skin, nerves and mucous membranes. Once present, common signs and symptoms include skin lesions; muscle weakness or paralysis; eye problems that may lead to blindness; nosebleeds; severe pain; and/or numbness in the hands, feet, arms and legs. Hansen's disease is caused by the bacterium Mycobacterium leprae; however, the way in which the bacterium is transmitted (spread) is poorly understood. It appears that only about 5% of people are susceptible to the condition.

Disease Ontology: 11 A primary bacterial infectious disease that results in infection located in superficial peripheral nerves, located in skin, located in mucous membranes of the upper respiratory tract, located in anterior chamber of the eyes, or located in testes, has material basis in Mycobacterium leprae, which is transmitted by aerosol spread from infected nasal secretions to exposed nasal and oral mucosa. The infection has symptom skin lesions, has symptom sensory loss, has symptom motor loss and has symptom eye damage.

Orphanet: 58 A chronic infectious disease affecting primarily the skin and peripheral nervous system.

Wikipedia: 75 Leprosy, also known as Hansen's disease (HD), is a long-term infection by the bacteria Mycobacterium... more...

More information from OMIM: 246300

Related Diseases for Leprosy 3

Diseases in the Leprosy 3 family:

Leprosy 2 Leprosy 1
Leprosy 4 Leprosy 5
Leprosy 6

Diseases related to Leprosy 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1330)
# Related Disease Score Top Affiliating Genes
1 borderline leprosy 33.2 TLR2 SLC11A1 SDHD MLLT1 CD4 CCDC122
2 indeterminate leprosy 33.1 SLC11A1 SDHD PACRG CCDC122
3 tuberculoid leprosy 33.0 TNF TLR2 TLR1 SLC11A1 SDHD PACRG
4 erythema nodosum 32.1 TNF NOD2 IL10 IFNG
5 neuritis 31.9 TNF IL4 IL10 IFNG
6 syphilis 31.6 TNF TLR2 CD8A CD4 CCR6
7 leishmaniasis 31.5 TNF TLR2 SLC11A1 IL4 IL2 IL10
8 peripheral nervous system disease 31.5 TNF LRRK2 IL4 IL2 IL10 IFNG
9 anterior uveitis 31.3 TNF TLR2 IL2 IL10 IFNG CD8A
10 sarcoidosis 1 31.3 TNF SLC11A1 NOD2 IL2 IL10 IFNG
11 allergic disease 31.3 TNF IL4 IL2 IL10 IFNG CD8A
12 uveitis 31.3 TNF NOD2 IL4 IL2 IL10 IFNG
13 skin disease 31.2 TNF TLR2 NOD2 IL4 IL2 IL10
14 keratitis, hereditary 31.2 TNF TLR2 IL10 CD8A CD4 CCR6
15 iridocyclitis 31.2 TNF IL10 CD8A CD4
16 bell's palsy 31.2 TNF CD8A CD4
17 filarial elephantiasis 31.2 TNF TLR2 IL4 IL2 IL10 CD8A
18 chronic granulomatous disease 31.2 TNF IFNG CD8A CD4
19 human immunodeficiency virus type 1 31.1 IL2 IL10 IFNG CD4
20 dermatophytosis 31.1 TNF CD4 CCR6
21 mycobacterium tuberculosis 1 31.1 TNF TLR2 TLR1 SLC11A1 NOD2 IL4
22 scabies 31.1 IL4 CD8A CD4 CCR6
23 alopecia 31.1 TNF IL4 IL2 IFNG
24 facial paralysis 31.1 TNF CD8A CD4
25 exanthem 31.1 TNF IL4 IL2 IL10 IFNG CD8A
26 cutaneous leishmaniasis 31.1 TNF IL4 IL2 IL10 IFNG CD8A
27 autoimmune disease 31.1 TNF SLC11A1 IL4 IL2 IL10 IFNG
28 acquired immunodeficiency syndrome 31.0 TNF IL2 IL10 IFNG CD4
29 filariasis 31.0 TNF TLR2 TLR1 IL4 IL2 IL10
30 iritis 31.0 TNF NOD2 IL10 CD8A CD4 CCR6
31 visceral leishmaniasis 31.0 TNF TLR2 SLC11A1 IL4 IL2 IL10
32 tetanus 31.0 TNF IL4 IL2 IL10 IFNG
33 henoch-schoenlein purpura 31.0 TNF CD4 CCR6
34 deficiency anemia 31.0 TNF SLC11A1 IL2 IL10 CD8A CD4
35 fungal infectious disease 31.0 TNF TLR2 IL4 IL2 IL10 IFNG
36 psoriasis 31.0 TNF TLR2 NOD2 IL4 IL2 IL10
37 dermatitis 31.0 TNF NOD2 IL4 IL2 IL10 IFNG
38 tenosynovitis 30.9 TNF NOD2 CD8A CD4
39 immune deficiency disease 30.9 TNF TLR2 IL4 IL2 IL10 IFNG
40 mycosis fungoides 30.9 IL4 IL2 IFNG CCR6
41 elephantiasis 30.9 IL4 IL10 CD4
42 interstitial nephritis 30.9 TNF CD8A CD4 CCR6
43 vitiligo-associated multiple autoimmune disease susceptibility 1 30.9 TNF IL2 CD8A CD4 CCR6
44 pfeiffer syndrome 30.9 TNF IL2 IL10 CD8A CD4 CCR6
45 granuloma annulare 30.8 TNF CD8A CD4
46 granulomatous dermatitis 30.8 TNF NOD2 CD8A CD4
47 erythema multiforme 30.8 TNF IL4 IL2 IFNG
48 lymphadenitis 30.8 TNF SLC11A1 NOD2 IL10 IFNG CCR6
49 skin sarcoidosis 30.8 TNF IL2 IFNG CD8A CD4 CCR6
50 osteomyelitis 30.8 TNF TLR2 NOD2 IL4 IL10 IFNG

Comorbidity relations with Leprosy 3 via Phenotypic Disease Network (PDN):


Acute Cystitis

Graphical network of the top 20 diseases related to Leprosy 3:



Diseases related to Leprosy 3

Symptoms & Phenotypes for Leprosy 3

Human phenotypes related to Leprosy 3:

58 30 (show all 49)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 skeletal muscle atrophy 58 30 Frequent (33%) Frequent (79-30%)
HP:0003202
2 hyperkeratosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000962
3 hypohidrosis 58 30 Frequent (33%) Frequent (79-30%)
HP:0000966
4 paresthesia 58 30 Frequent (33%) Frequent (79-30%)
HP:0003401
5 sparse body hair 58 30 Frequent (33%) Frequent (79-30%)
HP:0002231
6 impaired temperature sensation 58 30 Frequent (33%) Frequent (79-30%)
HP:0010829
7 skin nodule 58 30 Frequent (33%) Frequent (79-30%)
HP:0200036
8 acute episodes of neuropathic symptoms 58 30 Frequent (33%) Frequent (79-30%)
HP:0003489
9 hypopigmented macule 58 30 Frequent (33%) Frequent (79-30%)
HP:0020073
10 abnormal autonomic nervous system physiology 58 30 Frequent (33%) Frequent (79-30%)
HP:0012332
11 enlarged peripheral nerve 58 30 Frequent (33%) Frequent (79-30%)
HP:0012645
12 dissociated sensory loss 58 30 Frequent (33%) Frequent (79-30%)
HP:0010835
13 acral ulceration 58 30 Frequent (33%) Frequent (79-30%)
HP:0006121
14 alopecia 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001596
15 epistaxis 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000421
16 steppage gait 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0003376
17 corneal ulceration 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012804
18 foot dorsiflexor weakness 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0009027
19 constrictive median neuropathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012185
20 absent eyebrow 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002223
21 verrucous papule 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012500
22 facial shape deformation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011334
23 loss of eyelashes 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0011457
24 decreased corneal sensation 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0012155
25 abnormality of the upper respiratory tract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002087
26 urticarial plaque 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030351
27 abnormality of the seventh cranial nerve 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0010827
28 penetrating foot ulcers 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001026
29 paralytic lagophthalmos 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0030003
30 dysesthesia 30 Occasional (7.5%) HP:0012534
31 abnormal facial skeleton morphology 30 Occasional (7.5%) HP:0011821
32 blindness 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000618
33 abnormality of the liver 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001392
34 glaucoma 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000501
35 abnormality of the adrenal glands 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000834
36 uveitis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000554
37 gynecomastia 58 30 Very rare (1%) Very rare (<4-1%)
HP:0000771
38 abnormality of the spleen 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001743
39 abnormality of bone marrow cell morphology 58 30 Very rare (1%) Very rare (<4-1%)
HP:0005561
40 iritis 58 30 Very rare (1%) Very rare (<4-1%)
HP:0001101
41 corneal perforation 58 30 Very rare (1%) Very rare (<4-1%)
HP:0100583
42 testicular mass 58 30 Very rare (1%) Very rare (<4-1%)
HP:0032404
43 muscle weakness 58 Occasional (29-5%)
44 abnormality of the immune system 30 HP:0002715
45 peripheral neuropathy 58 Very frequent (99-80%)
46 autoamputation of digits 58 Occasional (29-5%)
47 entrapment neuropathy 58 Frequent (79-30%)
48 hyperalgesia 58 Occasional (29-5%)
49 abnormality of facial skeleton 58 Occasional (29-5%)

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Immunology:
susceptibility to infection by mycobacterium leprae causing leprosy

Clinical features from OMIM®:

246300 (Updated 08-Dec-2022)

Symptoms:

11
  • skin lesions
  • sensory loss
  • motor loss
  • eye damage

MGI Mouse Phenotypes related to Leprosy 3:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 normal MP:0002873 10.06 CCR6 CD8A IFNG IL10 IL4 LRRK2
2 endocrine/exocrine gland MP:0005379 10.06 CD4 CD8A IFNG IL10 IL2 IL4
3 neoplasm MP:0002006 10.03 IFNG IL10 IL2 MLLT1 SDHD SLC11A1
4 cellular MP:0005384 9.93 CD4 CD8A IFNG IL10 IL2 IL4
5 no phenotypic analysis MP:0003012 9.91 CD4 IFNG IL10 IL2 IL4 LRRK2
6 digestive/alimentary MP:0005381 9.91 CD4 IFNG IL10 IL2 IL4 NOD2
7 immune system MP:0005387 9.83 CCR6 CD4 CD8A IFNG IL10 IL2
8 hematopoietic system MP:0005397 9.55 CCDC122 CCR6 CD4 CD8A IFNG IL10

Drugs & Therapeutics for Leprosy 3

Drugs for Leprosy 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 73)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
2
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
3 Vitamins Phase 4
4 Anti-Bacterial Agents Phase 4
5 Anti-Infective Agents Phase 4
6 Folic Acid Antagonists Phase 4
7 Folate Phase 4
8 Vitamin B9 Phase 4
9 Antiprotozoal Agents Phase 4
10 Antiparasitic Agents Phase 4
11 Vitamin B Complex Phase 4
12 Antimalarials Phase 4
13
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3 302-25-0
14
Prednisolone acetate Approved, Vet_approved Phase 2, Phase 3 52-21-1
15
Prednisolone Approved, Vet_approved Phase 2, Phase 3 50-24-8 4894 5755
16
Methylprednisolone hemisuccinate Approved Phase 2, Phase 3 2921-57-5 1875
17
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3 83-43-2 4159 6741
18
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
19
Clotrimazole Approved, Vet_approved Phase 2, Phase 3 23593-75-1 2812
20
Amitriptyline Approved Phase 3 50-48-6 2160
21
Tramadol Approved, Investigational Phase 3 27203-92-5 33741 5523
22
Bedaquiline Approved Phase 3 843663-66-1 5388906
23
Prednisolone hemisuccinate Experimental Phase 2, Phase 3 2920-86-7 4897
24 Immunosuppressive Agents Phase 2, Phase 3
25 Hormones Phase 2, Phase 3
26 Hormone Antagonists Phase 2, Phase 3
27 Antirheumatic Agents Phase 2, Phase 3
28 Antineoplastic Agents, Hormonal Phase 2, Phase 3
29 Calcineurin Inhibitors Phase 2, Phase 3
30 Cyclosporins Phase 2, Phase 3
31 Antifungal Agents Phase 2, Phase 3
32 glucocorticoids Phase 2, Phase 3
33
Methylprednisolone Acetate Phase 2, Phase 3 584547
34 Immunologic Factors Phase 2, Phase 3
35 Analgesics Phase 3
36 Neurotransmitter Agents Phase 3
37 Adrenergic Agents Phase 3
38 Psychotropic Drugs Phase 3
39 Antidepressive Agents, Tricyclic Phase 3
40 Antidepressive Agents Phase 3
41 Analgesics, Opioid Phase 3
42 Analgesics, Non-Narcotic Phase 3
43 Narcotics Phase 3
44 Antitubercular Agents Phase 3
45 Antibiotics, Antitubercular Phase 3
46 Immunoglobulin M Phase 3
47
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
48
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
49
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
50 CC-11050 Investigational Phase 2 340019-69-4

Interventional clinical trials:

(show all 37)
# Name Status NCT ID Phase Drugs
1 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
2 Effect of Additional Clofazimine on ENL Reactions in Leprosy Completed NCT01290744 Phase 4 Clofazimine;Placebo
3 Independent Study to Establish the Efficacy of the Six Doses Uniform MDT Regimen (U-MDT) for Leprosy Patients Completed NCT00669643 Phase 4 PB 6 doses - Rifampicin and Dapsone;PB 6 doses - Rifampicin, Clofazimine and Dapsone;MB 12 doses - Rifampicin, Clofazimine and Dapsone;MB 6 doses - Rifampicin, Clofazimine and Dapsone
4 Population Pharmacokinetic Analysis of Dapsone in Normal, Overweight and Obese Volunteers Completed NCT01165840 Phase 4 Dapsone
5 A Randomised Double Blind Controlled Trial Comparing Ciclosporin and Prednisolone in the Treatment of New Leprosy Type 1 Reactions Completed NCT00919815 Phase 2, Phase 3 Ciclosporin;Prednisolone
6 Treatment of Neuropathic Pain in Leprosy: a Randomized Double Blind Controlled Study Active, not recruiting NCT03324035 Phase 3 Amitriptyline;Placebo oral capsule;Tramadol
7 Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Active, not recruiting NCT03662022 Phase 3 Rifampicin
8 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 3 Study Not yet recruiting NCT05597280 Phase 3 BE-PEP Bedaquiline;SDR-PEP Rifampicin;BE-PEP Rifampicin
9 Two New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Phase II Study in a Leprosy-Endemic Region Completed NCT00128193 Phase 2
10 A Pilot Double Blind Controlled Study Randomizing Patients Whose ENL is Not Controlled With Standard Prednisolone, and Comparing a Group Treated With Ciclosporin to a Group Treated With Additional Steroid Only. Completed NCT00919776 Phase 2 prednisolone;ciclosporin
11 A Pilot (Double Blind Controlled) Study Randomizing Patients With New Acute ENL to Treatment Either With Ciclosporin or Prednisolone. Completed NCT00919542 Phase 2 Ciclosporin;prednisolone
12 A Pilot Study Assessing the Efficacy and Safety of Ciclosporin as a Second -Line Drug in Patients With Type 1 Reactions Who Have Not Responded to a 12 Week Course of Prednisolone. Completed NCT00919451 Phase 2 ciclosporin
13 Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy: Phase 2 Study Recruiting NCT05406479 Phase 2 BE-PEP (Bedaquiline);SDR-PEP;BE-PEP (Rifampicine)
14 A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum Recruiting NCT03807362 Phase 2 CC-11050
15 An Open-Label Study to Evaluate the Efficacy and Safety of TMC207 in Subjects With Multibacillary Leprosy Active, not recruiting NCT03384641 Phase 2 Bedaquiline 200 mg
16 Efficacy and Tolerability of Adjunct Metformin in Combination With Multidrug Treatment for Multibacillary Leprosy: A Randomized Double-blind, Controlled Proof-of-Concept Phase 2 Trial in Indonesia Not yet recruiting NCT05243654 Phase 2 Metformin;Placebo
17 A Phase 1b / 2a, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Adult Participants in Areas Endemic for Leprosy Not yet recruiting NCT03947437 Phase 1, Phase 2
18 The Effects of Virgin Coconut Oil Supplementation on Oxidative Stress and Treatment Response Among Hansen's Disease Patients on Multi-Drug Therapy: A Pilot Study Withdrawn NCT01885611 Phase 1, Phase 2
19 Phase I Study to Evaluate New Leprosy Skin Test Antigens: MLSA-LAM and MLCwA Completed NCT01920750 Phase 1
20 Proposal Evaluation and Intervention Through Prevention of Disability in Leprosy Patients Completed NCT01006759 Phase 1
21 A Phase 1, Open Label, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Subjects Completed NCT03302897 Phase 1
22 Evaluation of Low Level Laser Therapy Effects in Peripheral Nerves Patient Affected With Leprosy : Randomized Controlled Trial Unknown status NCT03072004
23 Montelukast as an Alternative or Supplementary Treatment in ENL Reaction in Leprosy Unknown status NCT00406861 montelukast in treatment of ENL reaction
24 Prevalence Survey for Innovative and Intensified Disease Management (IDM) Neglected Tropical Diseases (NTDs): A Cluster Randomised Two-stage Active Case Search for IDM-NTDs in Liberia Unknown status NCT03683745
25 Observation of Microcirculation Impairment in Patients With Lepromatous Leprosy Using Orthogonal Polarization Spectral (OPS) Imaging and Laser Doppler Iontophoresis Completed NCT02085317 acetylcholine Iontophoresis;sodium nitroprusside Iontophoresis
26 Clinic-Epidemiological Evaluation of Ulcers in Leprosy Patients and the Use of Low Level Laser Therapy: a Randomized Clinical Trial Completed NCT00860717
27 Improved Understanding of Ongoing Transmission of Leprosy in the Comoros, a Region Hyperendemic for the Disease. Completed NCT03526718
28 Molecular Epidemiology of Leprosy in Colombia Completed NCT00138437
29 Educational Virtual Objects (The Virtual Human Project) Assessment Inserted in Learning Based on Team (Team-based Learning) in Leprosy Education on Undergraduate Medical Setting Completed NCT02484469
30 Molecular Epidemiology of Leprosy - Philippines Completed NCT00315809
31 Modified Tarsorrhaphy vs Gold Weight Implant Technique for Paralytic Lagophthalmos Treatment in Leprosy Patients: a Randomized Clinical Trial Completed NCT04944498
32 The Evaluation of Treatment of Leprosy Wounds With Traditional Chinese Herbal Medicine Complex "Jingchuang Ointment" Recruiting NCT05047809
33 Epidemiology of Leprosy in French Guiana Recruiting NCT05031091
34 A Clinical Study on the Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients in Taiwan Recruiting NCT05091216
35 Clofazamine in the Long Term Treatment of Leprosy, Phase III No longer available NCT00852345 clofazamine
36 CD8 Reactivity to Microorganisms in Blood and Breast Milk Terminated NCT03084614
37 Prospective Randomized Controlled Trial Comparing Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer. Terminated NCT01751503

Search NIH Clinical Center for Leprosy 3

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Thalidomide

Cochrane evidence based reviews: leprosy

Genetic Tests for Leprosy 3

Genetic tests related to Leprosy 3:

# Genetic test Affiliating Genes
1 Leprosy, Susceptibility to, 3 28 TLR2

Anatomical Context for Leprosy 3

Organs/tissues related to Leprosy 3:

FMA: Superficial Peripheral Nerves, Skin, Mucous Membranes Of The Upper Respiratory Tract, Anterior Chamber Of The Eyes, Testes
MalaCards : Skin, Spinal Cord, Testes, Eye, Bone Marrow, Brain, Skeletal Muscle

Publications for Leprosy 3

Articles related to Leprosy 3:

(show top 50) (show all 22150)
# Title Authors PMID Year
1
No involvement of non-synonymous TLR2 polymorphisms in Japanese leprosy patients. 62 57 5
19111445 2009
2
TLR2 Arg677Trp polymorphism in leprosy: revisited. 62 57 5
15726416 2005
3
Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. 62 57 5
12646604 2003
4
Detection of Toll-like receptor 2 (TLR2) mutation in the lepromatous leprosy patients. 62 57 5
11476982 2001
5
Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. 62 57
18177245 2008
6
A family of human receptors structurally related to Drosophila Toll. 57
9435236 1998
7
Central Nervous System Mycobacterium Infection: Tuberculosis and Beyond. 62
36404038 2023
8
Microfluidic electrochemical device for real-time culturing and interference-free detection of Escherichia coli. 62
36442949 2023
9
Molecular epidemiology and clinical-laboratory aspects of chromoblastomycosis in Mato Grosso, Brazil. 62
35869803 2022
10
A comprehensive insight into the anti-inflammatory properties of dapsone. 62
36125533 2022
11
Hansen's disease and COVID-19 co-infection in Brazil. 62
35775153 2022
12
Correction: The life experience of leprosy families in maintaining interaction patterns in the family to support healing in leprosy patients in Indonesian society. A phenomenological qualitative study. 62
36454737 2022
13
Can anti-PGL-I antibody isotypes differentiate leprosy contacts and leprosy patients? 62
34974816 2022
14
Leprosy Caused by Mycobacterium lepromatosis. 62
36200553 2022
15
Lepromatous leprosy. 62
36116975 2022
16
Global epidemiology of leprosy from 2010 to 2020: A systematic review and meta-analysis of the proportion of sex, type, grade 2 deformity and age. 62
35510339 2022
17
In the footsteps of Albert Calmette: an ecological study of TB, leprosy and potential exposure to wild-type Mycobacterium bovis. 62
35460554 2022
18
Leprosy among female prisoners in Brazil. 62
36383862 2022
19
Pyrexia of unknown origin-a rare presentation of disseminated leprosy in the bone marrow. 62
36214852 2022
20
Leonine facies and madarosis in lepromatous leprosy. 62
34588291 2022
21
Suspicious symptom monitoring for leprosy: an optimal practice for early detection under a low endemic situation in Zhejiang Province, China. 62
35913701 2022
22
Reactions in leprosy patients triggered by COVID-19 vaccination - a cross-sectional study from a tertiary care centre in India. 62
35771128 2022
23
Pathogenicity and virulence of Mycobacterium leprae. 62
36326715 2022
24
Hypopigmented Skin Lesions with Doubtful/Minimal Sensory Impairment: A Histopathology-Based Analysis. 62
36386740 2022
25
Virchowian leprosy madarosis: histological evidence of a permanent non-cicatricial alopecia. 62
35771122 2022
26
Clinical and epidemiological trends in childhood leprosy: A 20-year retrospective analysis from a tertiary care hospital in Jammu, North India. 62
35146981 2022
27
Leprosy rash precipitated by immunotherapy for suspected inflammatory neuropathy. 62
36428101 2022
28
Role of molecular approaches to distinguish post kala-azar dermal leishmaniasis from leprosy: A case study. 62
36461804 2022
29
Epidemiological scenario of leprosy in marginalized communities of India: Focus on scheduled tribes. 62
36348589 2022
30
Activated TLR2/4-positive T cells boost cell exhaustion during lepromatous leprosy infection via PD-1 upregulation. 62
36419668 2022
31
Stigma towards leprosy across seven life domains in Indonesia: a qualitative systematic review. 62
36450432 2022
32
Ancient DNA confirmation of lepromatous leprosy in a skeleton with concurrent osteosarcoma, excavated from the leprosarium of St. Mary Magdalen in Winchester, Hants., UK. 62
36114431 2022
33
A-waves are associated with neuropathic pain in leprosy. 62
36420641 2022
34
Time to be vigilant in contacts of leprosy for possible single-dose rifampicin. 62
36212896 2022
35
Should we persist with the term Lazarine leprosy? A historical perspective. 62
36332094 2022
36
Musculoskeletal manifestations of leprosy. 62
35323918 2022
37
Acquired acoria and iris pearls in leprosy: Case report. 62
34142579 2022
38
Asymmetrical ocular affliction in a case of recurrent erythema nodosum leprosum-an uncommon manifestation of leprosy in contemporary times. 62
35405022 2022
39
Lepromatous leprosy with central serous chorioretinopathy. 62
36331860 2022
40
Interleukin-17A in Egyptian leprosy patients: a clinical, genetic, and biochemical study. 62
36153175 2022
41
A spectrum of leprosy reactions triggered by Covid-19 vaccination: a series of four cases. 62
35766884 2022
42
Epidemiological Characteristics and Factors Associated with Cure of Leprosy in Chongqing, China, from 1949 to 2019. 62
36410327 2022
43
Recording of Leprosy Cases in India: Need for a User-Friendly and Effective App. 62
36386737 2022
44
Case of borderline leprosy presenting with urticaria-like eruptions and limbs swelling: A lesson to be learned for dermatologists. 62
35665532 2022
45
Solitary plaque of borderline lepromatous leprosy clinically masquerading as paucibacillary leprosy. 62
36384324 2022
46
Multi-bacillary leprosy under the Chinese leprosy elimination program. 62
36038425 2022
47
Leprosy and HIV can cause recurrent facial palsy. 62
36368704 2022
48
Phenolic glycolipid-1 of Mycobacterium leprae is involved in human Schwann cell line ST8814 neurotoxic phenotype. 62
36349509 2022
49
Hemophagocytic Lymphohistiocytosis in Erythema Nodosum Leprosum: Case Report of an Unusual Conundrum. 62
36386753 2022
50
Identification of shared loci associated with both Crohn's disease and leprosy in East Asians. 62
35512355 2022

Variations for Leprosy 3

ClinVar genetic disease variations for Leprosy 3:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TLR2 NM_001318789.2(TLR2):c.2029C>T (p.Arg677Trp) SNV Risk Factor
6663 rs121917864 GRCh37: 4:154626088-154626088
GRCh38: 4:153704936-153704936
2 TLR2 NM_001318789.2(TLR2):c.1340G>A (p.Arg447Gln) SNV Uncertain Significance
992555 rs374122287 GRCh37: 4:154625399-154625399
GRCh38: 4:153704247-153704247

Copy number variations for Leprosy 3 from CNVD:

6
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 255081 9 72339785 73251640 Duplication TRPM3 Leprosy

Expression for Leprosy 3

Search GEO for disease gene expression data for Leprosy 3.

Pathways for Leprosy 3

Pathways related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.95 CCR6 CD4 CD8A IFNG IL10 IL2
2
Show member pathways
13.4 TNF TLR2 TLR1 IL4 IL2 IL10
3
Show member pathways
13.3 TNF NOD2 IL4 IL2 IL10 IFNG
4
Show member pathways
12.59 TNF IL2 IL10 IFNG CD4
5 12.57 CD8A IFNG IL10 IL2 IL4 TLR1
6
Show member pathways
12.48 TNF TLR2 TLR1 NOD2
7
Show member pathways
12.42 TNF TLR2 TLR1 IL4 IFNG
8
Show member pathways
12.32 TLR2 TLR1 SLC11A1 CD4 CCR6
9
Show member pathways
12.19 IFNG IL2 IL4 TNF
10 12.18 TNF TLR2 TLR1 IFNG
11 12.1 TNF IL4 IL10 IFNG
12
Show member pathways
12.09 TNF IL4 IL2 IL10 IFNG CD8A
13
Show member pathways
12.02 IL4 IL2 IFNG CD8A CD4
14 12 TNF IL4 IL2 IFNG
15 11.93 CD4 CD8A IFNG IL10 IL2 IL4
16 11.92 TNF LRRK2 IL4 IL2 IL10 IFNG
17
Show member pathways
11.91 TLR2 TLR1 IL4 IFNG CD4
18
Show member pathways
11.8 TNF TLR2 TLR1 IL2 IL10 IFNG
19 11.79 TNF IL4 IL2 IL10 IFNG
20 11.78 IL2 IL10 IFNG CD4
21 11.75 TNF IL2 IL10 IFNG CD8A CD4
22 11.74 IL4 IL2 IFNG
23 11.74 IL4 IL2 IFNG CD4
24 11.73 IL4 IL2 IL10 IFNG
25
Show member pathways
11.71 TNF IL4 IL2 IFNG
26
Show member pathways
11.65 TNF IL2 IFNG
27 11.59 TNF IL4 IL2 IL10 IFNG CD4
28 11.56 TNF NOD2 IFNG
29 11.56 IL4 IL2 IL10 IFNG CD4
30 11.53 TNF TLR2 IFNG
31
Show member pathways
11.42 TNF IL2 IL10 IFNG
32 11.34 IL4 IL2 IFNG
33 11.32 IFNG IL4 TNF
34
Show member pathways
11.27 TNF TLR2 NOD2 IL4 IL2 IL10
35 11.26 IL4 IL2 IL10 IFNG
36 11.26 TNF IL4 IL2 IL10 IFNG
37 11.24 IL2 IFNG CD4
38 11.18 TLR2 TLR1 IFNG
39 11.13 TNF IL4 IL2 IL10 IFNG CD8A
40 11.1 TNF IL4 IL2 IL10 IFNG CD4
41 11 CD4 IFNG IL2 IL4
42 10.69 IL2 IFNG

GO Terms for Leprosy 3

Cellular components related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.18 TNF TLR2 TLR1 SLC11A1 CD8A CD4
2 plasma membrane GO:0005887 10.18 TNF TLR2 TLR1 SLC11A1 CD8A CD4
3 membrane raft GO:0045121 9.65 TNF TLR2 TLR1 LRRK2 CD4
4 Toll-like receptor 1-Toll-like receptor 2 protein complex GO:0035354 8.92 TLR2 TLR1

Biological processes related to Leprosy 3 according to GeneCards Suite gene sharing:

(show all 34)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of inflammatory response GO:0050729 10.21 IFNG IL2 TLR2 TNF
2 calcium-mediated signaling GO:0019722 10.18 CCR6 CD4 LRRK2 TNF
3 positive regulation of chemokine production GO:0032722 10.13 TNF TLR2 IFNG
4 positive regulation of cytokine production GO:0001819 10.13 IFNG IL10 SLC11A1 TNF
5 positive regulation of interleukin-12 production GO:0032735 10.12 TLR2 NOD2 IFNG
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 10.11 TNF IL4 IL2 IFNG
7 positive regulation of interleukin-10 production GO:0032733 10.1 TLR2 NOD2 IL4
8 positive regulation of interleukin-8 production GO:0032757 10.1 TNF TLR2 TLR1 NOD2
9 immune system process GO:0002376 10.02 TLR2 TLR1 NOD2 LACC1 IL2 CD8A
10 positive regulation of tumor necrosis factor production GO:0032760 10.02 IFNG LRRK2 NOD2 TLR1 TLR2
11 macrophage activation GO:0042116 10.01 TLR1 SLC11A1 IL4
12 positive regulation of phagocytosis GO:0050766 9.97 TNF SLC11A1 NOD2 IFNG
13 neuroinflammatory response GO:0150076 9.96 IL4 IFNG
14 toll-like receptor 2 signaling pathway GO:0034134 9.96 TLR2 NOD2
15 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.96 TNF NOD2
16 positive regulation of interleukin-6 production GO:0032755 9.96 TNF TLR2 TLR1 NOD2 IFNG
17 negative regulation of cytokine production involved in immune response GO:0002719 9.94 IL10 TNF
18 cellular response to bacterial lipopeptide GO:0071221 9.94 TLR1 TLR2
19 positive regulation of mononuclear cell migration GO:0071677 9.93 IL4 TNF
20 response to lipopolysaccharide GO:0032496 9.93 IL10 NOD2 SLC11A1 TLR2 TNF
21 regulation of isotype switching GO:0045191 9.92 IL4 IL10
22 negative regulation of interleukin-18 production GO:0032701 9.92 NOD2 IL10
23 positive regulation of plasma cell differentiation GO:1900100 9.91 IL2 IL10
24 positive regulation of MHC class II biosynthetic process GO:0045348 9.91 IL4 IL10 IFNG
25 cellular response to triacyl bacterial lipopeptide GO:0071727 9.9 TLR2 TLR1
26 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.89 TNF IFNG
27 positive regulation of nitrogen compound metabolic process GO:0051173 9.88 TNF IFNG
28 positive regulation of vitamin D biosynthetic process GO:0060557 9.87 TNF IFNG
29 detection of triacyl bacterial lipopeptide GO:0042495 9.86 TLR2 TLR1
30 chronic inflammatory response to antigenic stimulus GO:0002439 9.85 TNF IL10
31 cell activation GO:0001775 9.8 TNF TLR2 TLR1
32 microglial cell activation GO:0001774 9.76 TNF TLR2 IL4 IFNG
33 immune response GO:0006955 9.58 TNF TLR2 TLR1 SLC11A1 IL4 IL2
34 positive regulation of nitric-oxide synthase biosynthetic process GO:0051770 9.56 IFNG LRRK2 NOD2 TLR2

Molecular functions related to Leprosy 3 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.32 TNF IL4 IL2 IL10 IFNG

Sources for Leprosy 3

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....